nach oben

Current Treatment Options in Oncology

Erschienen in:

01.02.2020 | Sarcoma (SH Okuno, Section Editor)

Extremity Soft Tissue Sarcoma: Role of Local Control

verfasst von: Elyse J. Brinkmann, MD, Safia K. Ahmed, MD, Matthew T. Houdek, MD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Opinion statement

For localized extremity soft tissue sarcoma (eSTS), treatment is individualized and each patient needs to be evaluated by a multidisciplinary team at a referral sarcoma center specialized in the care of sarcoma. For a majority of patients, treatment for eSTS involves limb-salvage surgery, with or without the addition of radiation therapy. Surgery should only be performed by surgeons specifically fellowship trained in the resection of eSTS. Surgery alone may be considered for small, low-grade, and superficial tumors as long a wide (≥ 2 cm) margin can be achieved. In cases where a less than wide negative margin can be achieved, radiation therapy should be utilized to facilitate a planned close margin resection to preserve critical structures (such as nerves, blood vessels, and bone) without a significant impact on oncologic outcomes. Soft tissue sarcomas are rare, and as such patients often present following an inadvertent excision. In these situations, we recommend preoperative radiation and wide tumor bed re-excision, as rates of residual tumor can be high in this scenario. While there is large amount of evidence to support the use of radiotherapy to enhance local tumor control, the evidence to support the use of chemotherapy to enhance local tumor control is lacking, and as such cannot be recommended for all patients.

Gronchi A, Colombo C, Raut CP. Surgical management of localized soft tissue tumors. Cancer. 2014;120(17):2638–48. https://doi.org/10.1002/cncr.28715.CrossRefPubMed

Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416–21; discussion 21-2. https://doi.org/10.1097/SLA.0000000000000869.CrossRefPubMedPubMedCentral

Jo VY, Doyle LA. Refinements in sarcoma classification in the current 2013 World Health Organization classification of tumours of soft tissue and bone. Surg Oncol Clin N Am. 2016;25(4):621–43. https://doi.org/10.1016/j.soc.2016.05.001.CrossRefPubMed

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv51–67. https://doi.org/10.1093/annonc/mdy096.CrossRefPubMed

Cates JMM. The AJCC 8th edition staging system for soft tissue sarcoma of the extremities or trunk: a cohort study of the SEER database. J Natl Compr Cancer Netw. 2018;16(2):144–52. https://doi.org/10.6004/jnccn.2017.7042.CrossRef

Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89. https://doi.org/10.1200/JCO.1996.14.5.1679.CrossRefPubMed

•• Lazarides AL, Kerr DL, Nussbaum DP, Kreulen RT, Somarelli JA, Blazer DG 3rd, et al. Soft tissue sarcoma of the extremities: what is the value of treating at high-volume centers? Clin Orthop Relat Res. 2019;477(4):718–27. https://doi.org/10.1097/01.blo.0000533623.60399.1b. Review of the national cancer database and showed that patients treated at a referal, high-volume cancer cnter were at low risk of death compared with those treated at a low-volume cancer center.CrossRefPubMed

Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand. 1994;65(1):47–50. https://doi.org/10.3109/17453679408993717.CrossRefPubMed

Von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(5):536–63. https://doi.org/10.6004/jnccn.2018.0025.CrossRef

10.

Pasquali S, Gronchi A. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(6):415–29. https://doi.org/10.1177/1758834017705588.CrossRefPubMedPubMedCentral

11.

Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81. https://doi.org/10.1002/cncr.23592.CrossRefPubMed

12.

Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54. https://doi.org/10.1016/S1470-2045(12)70346-7.CrossRefPubMed

13.

•• Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22. https://doi.org/10.1016/S1470-2045(17)30334-0. Prospective randomized study of patients with extremity soft tissue sarcoma showing that patients with histoloigcal tailored chemotherapy had worse survival compared with those receiving standard chemotherapy. Also showed the importance of using a chemotherapy with anthracycline-based chemotherapy.CrossRefPubMed

14.

•• Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, et al. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. Eur J Cancer. 2018;105:19–27. https://doi.org/10.1016/j.ejca.2018.09.028. Multicenter study showing the addition of chemotherapy leads to a 5% survival benefit in propensity matched analysis. Showed that radiotherapy impoved local control in all cases, however especially in certain hisologies such as myxoid liposarcoma, vascular sarcomas, and myxofibrosarcomas.CrossRefPubMed

15.

Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647–54.

16.

Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487–97. https://doi.org/10.1016/s1470-2045(02)00818-5.CrossRefPubMed

17.

Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561–70. https://doi.org/10.1016/S1470-2045(10)70071-1.CrossRefPubMedPubMedCentral

18.

Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review. Eur J Surg Oncol. 2013;39(4):311–9. https://doi.org/10.1016/j.ejso.2012.12.018.CrossRefPubMed

19.

O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41. https://doi.org/10.1016/s0140-6736(02)09292-9.CrossRefPubMed

20.

Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2002;20(22):4472–7. https://doi.org/10.1200/JCO.2002.03.084.CrossRefPubMed

21.

Davis AM, O’Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53. https://doi.org/10.1016/j.radonc.2004.12.020.CrossRefPubMed

22.

Chung PW, Deheshi BM, Ferguson PC, Wunder JS, Griffin AM, Catton CN, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009;115(14):3254–61. https://doi.org/10.1002/cncr.24375.CrossRefPubMed

23.

Haas RL, Miah AB, LePechoux C, DeLaney TF, Baldini EH, Alektiar K, et al. Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiother Oncol. 2016;119(1):14–21. https://doi.org/10.1016/j.radonc.2015.12.002.CrossRefPubMed

24.

Al Yami A, Griffin AM, Ferguson PC, Catton CN, Chung PW, Bell RS, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? Int J Radiat Oncol Biol Phys. 2010;77(4):1191–7. https://doi.org/10.1016/j.ijrobp.2009.06.074.CrossRefPubMed

25.

Pan E, Goldberg SI, Chen YL, Giraud C, Hornick JL, Nielsen GP, et al. Role of post-operative radiation boost for soft tissue sarcomas with positive margins following pre-operative radiation and surgery. J Surg Oncol. 2014;110(7):817–22. https://doi.org/10.1002/jso.23741.CrossRefPubMed

26.

Alamanda VK, Song Y, Shinohara E, Schwartz HS, Holt GE. Postoperative radiation boost does not improve local recurrence rates in extremity soft tissue sarcomas. J Med Imaging Radiat Oncol. 2014;58(5):633–40. https://doi.org/10.1111/1754-9485.12184.CrossRefPubMed

27.

Townley WA, Mah E, O’Neill AC, Wunder JS, Ferguson PC, Zhong T, et al. Reconstruction of sarcoma defects following pre-operative radiation: free tissue transfer is safe and reliable. J Plast Reconstr Aesthet Surg. 2013;66(11):1575–9. https://doi.org/10.1016/j.bjps.2013.06.029.CrossRefPubMed

28.

Bedi M, King DM, DeVries J, Hackbarth DA, Neilson JC. Does vacuum-assisted closure reduce the risk of wound complications in patients with lower extremity sarcomas treated with preoperative radiation? Clin Orthop Relat Res. 2019;477(4):768–74. https://doi.org/10.1097/CORR.0000000000000371.CrossRefPubMed

29.

Holt GE, Griffin AM, Pintilie M, Wunder JS, Catton C, O’Sullivan B, et al. Fractures following radiotherapy and limb-salvage surgery for lower extremity soft-tissue sarcomas. A comparison of high-dose and low-dose radiotherapy. J Bone Joint Surg Am. 2005;87(2):315–9. https://doi.org/10.2106/JBJS.C.01714.CrossRefPubMed

30.

Dickie CI, Parent AL, Griffin AM, Fung S, Chung PW, Catton CN, et al. Bone fractures following external beam radiotherapy and limb-preservation surgery for lower extremity soft tissue sarcoma: relationship to irradiated bone length, volume, tumor location and dose. Int J Radiat Oncol Biol Phys. 2009;75(4):1119–24. https://doi.org/10.1016/j.ijrobp.2008.12.006.CrossRefPubMed

31.

Patel SR. Radiation-induced sarcoma. Curr Treat Options in Oncol. 2000;1(3):258–61.CrossRef

32.

Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28(12):2064–9. https://doi.org/10.1200/JCO.2009.25.1728.CrossRefPubMedPubMedCentral

33.

Sheppard DG, Libshitz HI. Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. Clin Radiol. 2001;56(1):22–9. https://doi.org/10.1053/crad.2000.0599.CrossRefPubMed

34.

Li XA, Chen X, Zhang Q, Kirsch DG, Petersen I, DeLaney TF, et al. Margin reduction from image guided radiation therapy for soft tissue sarcoma: secondary analysis of Radiation Therapy Oncology Group 0630 results. Pract Radiat Oncol. 2016;6(4):e135–40. https://doi.org/10.1016/j.prro.2015.11.012.CrossRefPubMed

35.

O’Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013;119(10):1878–84. https://doi.org/10.1002/cncr.27951.CrossRefPubMed

36.

Folkert MR, Singer S, Brennan MF, Kuk D, Qin LX, Kobayashi WK, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J Clin Oncol. 2014;32(29):3236–41. https://doi.org/10.1200/JCO.2013.53.9452.CrossRefPubMedPubMedCentral

37.

Kosela-Paterczyk H, Szumera-Cieckiewicz A, Szacht M, Haas R, Morysinski T, Dziewirski W, et al. Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma. Eur J Surg Oncol. 2016;42(6):891–8. https://doi.org/10.1016/j.ejso.2016.02.258.CrossRefPubMed

38.•

Yuce Sari S, Cengiz M, Dauletkazin A, Yazici G, Gultekin M, Hurmuz P, et al. Hypofractionated radiotherapy for non-metastatic bone and soft tissue sarcomas. Cancer Radiother. 2019. https://doi.org/10.1016/j.canrad.2019.06.011. Early results of a heterogenous group of patients receiving hypofractionated radiotherapy showing this could be a promising way to treat patients with soft tissues sarcomas and may reduce the risk of complications.CrossRef

39.

Roeder F, Lehner B, Saleh-Ebrahimi L, Hensley FW, Ulrich A, Alldinger I, et al. Intraoperative electron radiation therapy combined with external beam radiation therapy and limb sparing surgery in extremity soft tissue sarcoma: a retrospective single center analysis of 183 cases. Radiother Oncol. 2016;119(1):22–9. https://doi.org/10.1016/j.radonc.2015.11.014.CrossRefPubMed

40.

• Roeder F, de Paoli A, Saleh-Ebrahimi L, Alldinger I, Bertola G, Boz G, et al. Intraoperative electron radiation therapy combined with external beam radiation therapy after gross total resection in extremity soft tissue sarcoma: a European pooled analysis. Ann Surg Oncol. 2018;25(13):3833–42. https://doi.org/10.1245/s10434-018-6787-9 Review of several studies examining the utility of intraoperative boost of radiotherapy and showed that intraoperative radiotherapy fails to salvage a positive margin in patients with soft tissue sarcoma and the authors recommend a re-excision when possible.CrossRefPubMed

41.

Naghavi AO, Fernandez DC, Mesko N, Juloori A, Martinez A, Scott JG, et al. American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. Brachytherapy. 2017;16(3):466–89. https://doi.org/10.1016/j.brachy.2017.02.004.CrossRefPubMed

42.

Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47(1):157–63. https://doi.org/10.1016/s0360-3016(99)00546-5.CrossRefPubMed

43.

Alekhteyar KM, Leung DH, Brennan MF, Harrison LB. The effect of external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin. Int J Radiat Oncol Biol Phys. 1996;36(2):321–4. https://doi.org/10.1016/s0360-3016(96)00331-8.CrossRefPubMed

44.

DeLaney TF, Haas RL. Innovative radiotherapy of sarcoma: proton beam radiation. Eur J Cancer. 2016;62:112–23. https://doi.org/10.1016/j.ejca.2016.04.015.CrossRefPubMed

45.

Fogliata A, Scorsetti M, Navarria P, Catalano M, Clivio A, Cozzi L, et al. Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy. Acta Oncol. 2013;52(3):545–52. https://doi.org/10.3109/0284186X.2012.689853.CrossRefPubMed

46.

Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med. 2016;8(320):320ra4. https://doi.org/10.1126/scitranslmed.aad0293.CrossRefPubMedPubMedCentral

47.

O’Donnell PW, Griffin AM, Eward WC, Sternheim A, Catton CN, Chung PW, et al. The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer. 2014;120(18):2866–75. https://doi.org/10.1002/cncr.28793.CrossRefPubMed

48.

Clarkson PW, Griffin AM, Catton CN, O’Sullivan B, Ferguson PC, Wunder JS, et al. Epineural dissection is a safe technique that facilitates limb salvage surgery. Clin Orthop Relat Res. 2005;438:92–6. https://doi.org/10.1097/01.blo.0000180057.22712.53.CrossRefPubMed

49.

•• Gundle KR, Kafchinski L, Gupta S, Griffin AM, Dickson BC, Chung PW, et al. Analysis of margin classification systems for assessing the risk of local recurrence after soft tissue sarcoma resection. J Clin Oncol. 2018;36(7):704–9. https://doi.org/10.1200/JCO.2017 Single center review of a prospective databased showing that planned close negative and planned close but ultimately positive margins around critical structures are safe when performed with the addition of radiotherapy.CrossRefPubMed

50.

Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, et al. Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg. 2006;76(3):104–9. https://doi.org/10.1111/j.1445-2197.2006.03615.x.CrossRefPubMed

51.

Novais EN, Demiralp B, Alderete J, Larson MC, Rose PS, Sim FH. Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin Orthop Relat Res. 2010;468(11):3003–11. https://doi.org/10.1007/s11999-010-1471-9.CrossRefPubMedPubMedCentral

52.

Vraa S, Keller J, Nielsen OS, Jurik AG, Jensen OM. Soft-tissue sarcoma of the thigh: surgical margin influences local recurrence but not survival in 152 patients. Acta Orthop Scand. 2001;72(1):72–7. https://doi.org/10.1080/000164701753606734.CrossRefPubMed

53.

Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, et al. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol. 2007;14(5):1583–90. https://doi.org/10.1245/s10434-006-9325-0.CrossRefPubMed

54.

Heslin MJ, Woodruff J, Brennan MF. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management. J Clin Oncol. 1996;14(2):473–8. https://doi.org/10.1200/JCO.1996.14.2.473.CrossRefPubMed

55.

Stojadinovich A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235(3):424–34. https://doi.org/10.1097/00000658-200203000-00015.CrossRef

56.

Tanabe KK, Pollock RE, Ellis LM, Murphy A, Sherman N, Romsdahl MM. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer. 1994;73(6):1652–9. https://doi.org/10.1002/1097-0142(19940315)73:6<1652::aid-cncr2820730617>3.0.co;2-x.CrossRefPubMed

57.

Bonvalot S, Levy A, Terrier P, Tzanis D, Bellefqih S, Le Cesne A, et al. Primary extremity soft tissue sarcomas: does local control impact survival? Ann Surg Oncol. 2017;24(1):194–201. https://doi.org/10.1245/s10434-016-5462-2.CrossRefPubMed

58.

Eccles C, Whitaker J, Nyland J, Roberts C, Carlson J, Zamora R. Skin fiducial markers enable accurate computerized navigation resection of simulated soft tissue tumors: a static cadaveric model pilot study. J Surg Oncol. 2018;118(3):510–7. https://doi.org/10.1002/jso.25155.CrossRefPubMed

59.

Mahjoub A, Morales-Restrepo A, Fourman MS, Mandell JB, Feiqi L, Hankins ML, et al. Tumor resection guided by intraoperative indocyanine green dye fluorescence angiography results in negative surgical margins and decreased local recurrence in an orthotopic mouse model of osteosarcoma. Ann Surg Oncol. 2019;26(3):894–8. https://doi.org/10.1245/s10434-018-07114-9.CrossRefPubMed

60.

Gustafson P. Soft tissue sarcoma. Acta Orthop Scand. 1994;Suppl 259(65):2–31. https://doi.org/10.3109/17453679409153928.CrossRef

61.

Salas S, Stoeckle E, Collin F, Bui B, Terrier P, Guillou L, et al. Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database. Eur J Cancer. 2009;45(12):2091–102. https://doi.org/10.1016/j.ejca.2009.03.006.CrossRefPubMed

62.

Tsukushi S, Nishida Y, Shido Y, Wasa J, Ishiquiro N. Clinicopathological prognostic factors of superficial non-small round cell soft tissue sarcomas. J Surg Oncol. 2012;105(7):668–72. https://doi.org/10.1002/jso.23025.CrossRefPubMed

63.

Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82(1):361–7. https://doi.org/10.1016/j.ijrobp.2010.08.042.CrossRefPubMed

64.

Ghazala CG, Agni NR, Ragbir M, Dildey P, Lee D, Rankin KS. Myxofibrosarcoma of the extremity and trunk: a multidisciplinary approach leads to good local rates of LOCAL control. Bone Joint J. 2016;98-B(12):1682–8. https://doi.org/10.1302/0301-620X.98B12.CrossRefPubMed

65.

Kikuta K, Kubota D, Yoshida A, Suzuki Y, Morioka H, Toyama Y, et al. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol. 2013;43(11):1093–104. https://doi.org/10.1093/jjco/hyt119.CrossRefPubMed

66.

Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004;35(5):612–21. https://doi.org/10.1016/j.humpath.2004.01.016.CrossRefPubMed

67.

Tsagozis P, Bauer HC, Styring E, Trovik CS, Zaikova O, Brosjo O. Prognostic factors and follow-up strategy for superficial soft-tissue sarcomas: analysis of 622 surgically treated patients from the scandinavian sarcoma group register. J Surg Oncol. 2015;111(8):951–6. https://doi.org/10.1002/jso.23927.CrossRefPubMed

68.

Austin JL, Temple WJ, Puloski S, Schachar NS, Oddone Paolucci E, Kurien E, et al. Outcomes of surgical treatment alone in patients with superficial soft tissue sarcoma regardless of size or grade. J Surg Oncol. 2016;113(1):108–13. https://doi.org/10.1002/jso.24091.CrossRefPubMed

69.

Eward WC, Lazarides AL, Griffin AM, O’Donnell PW, Sternheim A, O’Neill A, et al. Superficial soft-tissue sarcomas rarely require advanced soft-tissue reconstruction following resection. Plast Reconstr Surg Glob Open. 2017;5(11):e1553. https://doi.org/10.1097/GOX.0000000000001553.CrossRefPubMedPubMedCentral

70.

Chandrasekar CR, Wafa H, Grimer RJ, Carter SR, Tillman RM, Abudu A. The effect of unplanned excision of a soft-tissue sarcoma on prognosis. J Bone Joint Surg (Br). 2008;90(2):203–8. https://doi.org/10.1302/0301-620X.90B2.CrossRef

71.

Noria S, Davis A, Kandel R, Levesque J, O’Sullivan B, Wunder J, et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J Bone Joint Surg Am. 1996;78(5):650–5. https://doi.org/10.2106/00004623-199605000-00003.CrossRefPubMed

72.

•• Traub F, Griffin AM, Wunder JS, Ferguson PC. Influence of unplanned excisions on the outcomes of patients with stage III extremity soft-tissue sarcoma. Cancer. 2018;124(19):3868–75. https://doi.org/10.1002/cncr.31648. Large study of patients who present with high risk (large, deep, high-grade tumors) which were inadvertently excised. There was a high rate of residual disease, however with multidisciplinary care these cases are able to salvaged without an impact on oncologic outcome.CrossRefPubMed

73.

• Decanter G, Stoeckle E, Honore C, Meeus P, Mattei JC, Dubray-Longeras P, et al. Watch and wait approach for re-excision after unplanned yet macroscopically complete excision of extremity and superficial truncal soft tissue sarcoma is safe and does not affect metastatic risk or amputation rate. Ann Surg Oncol. 2019;26(11):3526–34. https://doi.org/10.1245/s10434-019-07494-6. Authors of this retrospective series question the dogma of re-excision in certain cases of extremity soft tissue sarcoma and offer a “wait and see” approach to certain patients who present after and inadvertent excision.CrossRefPubMed

74.

Sugiura H, Tsukushi S, Yoshida M, Nishida Y. What is the success of repeat surgical treatment of a local recurrence after initial wide resection of soft tissue sarcomas? Clin Orthop Relat Res. 2018;476(9):1791–800. https://doi.org/10.1007/s11999.0000000000000158.CrossRefPubMedPubMedCentral

75.

Montgomery C, Harris J, Siegel E, Suva L, Wilson M, Morell S, et al. Obesity is associated with larger soft-tissue sarcomas, more surgical complications, and more complex wound closures (obesity leads to larger soft-tissue sarcomas). J Surg Oncol. 2018;118(1):184–91. https://doi.org/10.1002/jso.25119.CrossRefPubMed

76.

Houdek MT, Griffin AM, Ferguson PC, Wunder JS. Morbid obesity increases the risk of postoperative wound complications, infection, and repeat surgical procedures following upper extremity limb salvage surgery for soft tissue sarcoma. Hand (N Y). 2019;14(1):114–20. https://doi.org/10.1177/1558944718797336.CrossRef

77.

Houdek MT, Hevesi M, Griffin AM, Wunder JS, Ferguson PC. Morbid obesity is associated with an increased risk of wound complications and infection after lower extremity soft-tissue sarcoma resection. J Am Acad Orthop Surg. 2019;27(21):807–15. https://doi.org/10.5435/JAAOS-D-18-00536.CrossRefPubMed

78.

Mattei JC, Brouste V, Terrier P, Bonvalot S, Lecesne A, Stoeckle E, et al. Distal extremities soft tissue sarcomas: are they so different from other limb localizations? J Surg Oncol. 2019;119(4):479–88. https://doi.org/10.1002/jso.25359.CrossRefPubMed

79.

Ferguson PC, Deheshi BM, Chung P, Catton CN, O’Sullivan B, Gupta A, et al. Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. Cancer. 2011;117(2):372–9. https://doi.org/10.1002/cncr.25418.CrossRefPubMed

80.

• Wigge S, Heissner K, Steger V, Ladurner R, Traub F, Sipos B, et al. Impact of surgery in patients with metastatic soft tissue sarcoma: a monocentric retrospective analysis. J Surg Oncol. 2018;118(1):167–76. https://doi.org/10.1002/jso.25115.Review of patients with metastatic soft tissue sarcoma and showed that reesction of extra pulmonary metastases can improve progression-free survival in some patients.CrossRefPubMedPubMedCentral

81.

• Pradhan A, Grimer RJ, Abudu A, Tillman RM, Carter SR, Jeys L, et al. Epithelioid sarcomas: how important is loco-regional control? Eur J Surg Oncol. 2017;43(9):1746–52. https://doi.org/10.1016/j.ejso.2017.07.002.Multicenter review of patients with epitheloid sarcoma, advocating for aggressive surgery in patients who present with isolated lymph node metastat disease in the absence of pulmonary metastases.CrossRefPubMed

82.

Davis AM, Wright JG, Williams JI, Bombardier C, Griffin A, Bell RS. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res. 1996;5(5):508–16. https://doi.org/10.1007/bf00540024.CrossRefPubMed

83.

Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241–6.

84.

Wilke B, Cooper A, Scarborough M, Gibbs P, Spiguel A. A comparison of limb salvage versus amputation for nonmetastatic sarcomas using patient-reported outcomes measurement information system outcomes. J Am Acad Orthop Surg. 2019;27(8):e381–e9. https://doi.org/10.5435/JAAOS-D-17-00758.CrossRefPubMed

Titel: Extremity Soft Tissue Sarcoma: Role of Local Control
verfasst von: Elyse J. Brinkmann, MD
Safia K. Ahmed, MD
Matthew T. Houdek, MD
Publikationsdatum: 01.02.2020
Verlag: Springer US
Erschienen in: Current Treatment Options in Oncology / Ausgabe 2/2020
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-020-0703-9

Springer Medizin

Extremity Soft Tissue Sarcoma: Role of Local Control

Opinion statement

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Dedifferentiated Liposarcoma: Systemic Therapy Options

Neoadjuvant Immunotherapy for Locally Advanced Melanoma

How Effective Is Palliative Care in Improving Patient Outcomes?

Patient Spirituality as a Component of Supportive Care: Assessment and Intervention

Nausea and Vomiting in Advanced Cancer

Cancer-Related Fatigue: Causes and Current Treatment Options

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie